Bioxytran Inc (BIXT)

[big rig 1]

This has the potential for a buyout or merger with a major. This is unbelievable and under the radar. Huge upside from here


BIG RIG

[Golden Cross]

Great news

[Ecomike]

What is a global patent for a non toxic to humans, A-Z viral cure worth? One hell of lot more that the 20 Million dollar market it closed at a day ago that is for sure. $BIXT

BIXT news just came out on the global patent for the non toxic to human antiviral that had a perfect drug trial and cured Covid19 in days, putting Paxlovid to shame and the BIXT carbohydrate based drug only took 2 days not 7-10 days and the BIXT had no bounce back of the covid ( so it was1 of only 2 perfect drug trials in decade, the other was the Hep C antiviral cure that is worth billions of dollars)

https://www.otcmarkets.com/stock/BIXT/news/Bioxytran-Gets-Broad-Patent-Coverage-on-60-Viruses?id=418645

Bioxytran Gets Broad Patent Coverage on 60+ Viruses
Press Release | 10/24/2023
Claims cover method of treating a viral infection with a lectin-binding carbohydrate

BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical-stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.

This is world wide patent people, not just the USA!!!

This could soon be the biggest thing since the invention of Penicillin, the first Antibiotic for pathogenic bacteria

This is the most undervalued Bio-Tech stock there is now!!!

[i_like_bb_stock]

news https://www.otcmarkets.com/stock/BIXT/news/Bioxytran-Gets-Broad-Patent-Coverage-on-60-Viruses?id=418645

[cashmagnet]

That's a really good point. With that in mind, I don't understand why this board has such low attendance. Bioxytran would appear to be one pink sheet stock that merits a little more excitement--unless I'm missing something about the company's true potential...

[Ecomike]

It just dawned on me what the huge potential revenue/applications for the

BIXT antiviral drugs would be for use to protect against terrorist Bio-warfare risks.

DOD should be funding this company.

[Retire43]

https://medium.com/[@ userid=1]-68-million-commitment-c6c9c3d2d859

[williams45]

At a trading price of $0.173, Bioxytran, Inc. ($BIXT) is a company to watch. With a 30-day average volume of over 208K, investor interest is growing as they pioneer solutions for hypoxia.

[cashmagnet]

Let's hope that even one of the fifty or so possible dance partners in the pharmaceutical sector decides to throw in with Bioxytran and make a lot of shareholders solvent and happy far into the future...We'll see...Hopefully soon...

[jedijazz]

$BIXT NEWS VIDEO
@BioxytranInc
(OTCQB: BIXT)

via
@YouTube
$WNW $ORTX $MSS $SP $ICU $CEI $BTTR $OMGA $OP $AVTX $EZGO $MKUL $VVOS

[Retire43]

Excellent talk today. Stock responses to the mentioning of a list of small cash rich companies that are perfect candidates to partner with BIXT!

[jedijazz]

$BIXT CEO Update @BioxytranInc (OTCQB: BIXT) Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia.

via @YouTube

[jedijazz]

Good afternoon $BIXT!

[BlazingStocks]

$BIXT Emerging Growth Conference
October 05, 2023

[INV4]

As filed with the Securities and Exchange Commission on September 18, 2023

Bioxytran Inc
Form S-1

===========

Selling Stockholders Resale Prospectus
The information in this Prospectus is not complete and may be changed. The Company may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This Prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

Subject to Completion, dated September 18, 2023

Preliminary Prospectus

Bioxytran, Inc.

18,578,982 Shares of Common Stock

This Prospectus relates to the resale by the investors listed in the section of this Prospectus entitled “Selling Stockholders” (the “Selling Stockholders”) of up to 18,578,982 shares (the “Shares”) of our Common Stock, par value $0.001 per share (“Common Stock”). The Shares consist of: (i) 11,000,000 shares of Common Stock (the “Offering Shares”) to be issued as an indirect primary offering to the Selling Stockholder pursuant to a Closing Agreement, dated September 18, 2023, by TRITON FUNDS LP (the “Closing Agreement”); (ii) 655,905 shares of Common Stock (the “Warrants”) issuable upon the exercise of a Warrant to Purchase Common Stock issued on September 14, 2023, to WallachBeth Capital, LLC and/or their affiliates pursuant to the Engagement Letter issued on the same day (the “Engagement Letter”); and (iii) 6,923,077 shares of Common Stock issuable upon the conversion of a $900,000 note with Walleye Opportunities Master Fund Ltd. (the “Walleye Note”), originally issued on May 3, 2021, and amended on May 5, 2023.

More info:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1445815/000149315223033028/forms-1.htm

[govprs]

Dilution??

[INV4]

Form EFFECT BIOXYTRAN, INC
October 2, 2023

United States Securities and exchange commission

Notice of Effectiveness

Effectiveness Date: September 29, 2023
Form: S-1
Company Name: BIOXYTRAN, INC.
File Number: 333-274576

More info:
https://www.sec.gov/Archives/edgar/data/1445815/999999999523002902/9999999995-23-002902-index.htm

https://www.sec.gov/cgi-bin/browse-edgar?filenum=333-274576&action=getcompany

==============

What is form S-1:
Form S-1. Form S-1 is an SEC filing used by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) as the "registration statement by the Securities Act of 1933". The S-1 contains the basic business and financial information on an issuer with respect to a specific securities offering.

Notice of effectiveness
Notice of effectiveness is a notice that transfers the control of a Controlled Account or a Collection Account to the Seller. It is used in various legal documents, such as registration rights agreements, put and settlement sheets, and exempt wholesale generator status.

[govprs]

What does it mean?

[INV4]

Form EFFECT - Notice of Effectiveness
October 02, 2023

https://ih.advfn.com/stock-market/USOTC/bioxytran-qb-BIXT/stock-news/92170151/form-effect-notice-of-effectiveness

[Retire43]

October 5 th


10:15 - 10:45?
Bioxytran, Inc. (OTCQB: BIXT)
Keynote speaker: Mike Sheikh, Executive Vice President Business Development

Note doesn’t state the est, cdt,

[PennyPusher786]

This company filing posted at 4pm:


September 26, 2023

 

Board of Directors

Bioxytran, Inc.

 

To Whom it May Concern:

 

In our capacity as counsel for Bioxytran, Inc. (the “Company”), we have participated in the corporate proceedings relative to the issuance by the Company of a maximum of 18,578,982 shares of Common Stock as set out and described in the Company’s Registration Statement on Form S-1 under the Securities Act of 1933 (the “Registration Statement”).

 

We have examined originals or copies, certified or otherwise identified to our satisfaction, of (i) the Registration Statement, (ii) the Company’s Articles of Incorporation, as amended to date, (iii) the Company’s Bylaws, (iv) certain resolutions of the Company’s board of directors and (v) such other documents as we have deemed necessary or appropriate for purposes of rendering the opinion set forth herein.

 

In our examination, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as certified or photostatic copies and the authenticity of the originals of such latter documents. As to any facts material to the opinion expressed herein that were not independently established or verified, we have relied upon statements and representations of officers and other representatives of the Company and others.

 

Based upon the foregoing, we opine that:

 

(1) The Company is a corporation duly organized and validly existing under the laws of the State of Nevada, as amended, including statutory provisions, and all applicable provisions of the Nevada Revised Statutes Chapter 78 Private Corporations and reported judicial decisions interpreting those laws;

 

(2) The Company has taken all requisite corporate action and all action required with respect to the authorization, issuance and sale of Common Stock issued pursuant to the Registration Statement;

 

(3) The 11,000,000 shares of Common Stock to be issued via an indirect primary offering to TRITON FUNDS LP (“TRITON”), pursuant to an amended Closing Agreement, once issued will be duly authorized, validly issued, fully paid and non-assessable.

 

(4) The 655,905 shares of Common Stock, issuable upon the exercise of Warrants to Purchase Common Stock (the “Warrants”), registered pursuant to the Registration Statement, once issued, will be duly authorized, validly issued, fully paid and non-assessable.

 

(5) The 6,923,077 shares of Common Stock, issuable upon the conversion of a convertible promissory Note (the “Note”), registered pursuant to the Registration Statement, once issued, will be duly authorized, validly issued, fully paid and non-assessable.

 

We hereby consent to the use of this opinion as an exhibit to the Registration Statement and to the references to the firm in the Registration Statement.

 

 Very truly yours,   WITHERSPOON BRAJCICH MCPHEE PLLC

 

A Professional Limited Liability Company

 

601 West Main Avenue, Suite 1400

Spokane, Washington 99201-0677

Telephone: [phone]

Facsimile: [phone]

Toll Free: [phone]

 

[jedijazz]

$BIXT Power hour up soon! PPS @ .218 +1.40% HOD .2224

[williams45]

With authorized shares totaling 300 million, $BIXT has ample room for growth and further research, increasing the potential for medical breakthroughs in hypoxia treatment.

[Retire43]

I agree with this statement “The drug can also work on Other corona viruses like the flue. This is going to be the best thing since sliced bread. “

[i_like_bb_stock]

works for me

[cashmagnet]

I get an error message when I click on the interview arrow. What's the correct link??

[cashmagnet]

OK thanks for your input Gov'--I appreciate it and hope this turns out well for all of us here eventually...

[williams45]

$BIXT authorization of 300 million shares indicates a strategic approach to future growth and expansion, aligning with its mission to combat hypoxia and save lives.

[i_like_bb_stock]

Nice interview!

[$theDDmessiah]

Looking good very promising

[Golden Cross]

Looking better here

[JoeForkeyBolo]

There have been only 2 companies that achieved 100% recovery in hospitalized patients. One was Bioxytran, the other was Todos Medical with Tollovir. Both small companies dealing with convertible debt financing. Todos share price has been decimated by one of their lenders. Another lender is way underwater but holding on without converting. I guess we will have to wait and see what happens with the lending here. If phase 3 has similar results to phase 2 trial, share price will take off and I expect company will be acquired by big Pharma.

[govprs]

Yes convertible and pipe financing usually lead to death spiral

I will try to read the s1 this weekend But I think it’s important to be extra careful here

If the drug really works they could bring in a partner like Moderna or someone big like that.

[JoeForkeyBolo]

That's always a risk with convertible debt. Some players better than others. I don't know the history of Triton or whether they're a good or bad player in funding small caps. One would think with he success of the phase 2 trial a funder would want to help the company achieve a successful phase 3 trial and FDA approval, not start dumping shares to trigger conversions at lower and lower prices, but I've seen it happen many times with other companies. Death-spiral financing is the term.

I plan on buying more shares and holding through the phase 3 trials.

[govprs]

Not sure. I was in another pinky and some triton fund was converting and dumping only thing that stopped them was the is maxed out so the couldn’t convert anymore

I could be wrong or confused
If this triton is legit then all good.

[cashmagnet]

Do you consider it bad news because Triton Funds is student run--or is your concern driven by some other issue? Just curious...

[govprs]

Triton isn’t good news. Imo

[williams45]

Breathe life back into ailing tissues with Bioxytran, Inc. ($BIXT). Their pharmaceutical advancements and 137,775,058 outstanding shares pave the way for recovery.

[Retire43]

Please share this!

Science buff #Investor #vaccinated #unvaccinated #COVID19 #LongCovid #Covid #masks #masksdontwork we want all to hear about a new paradigm in #drug development. $BIXT @buffalofireside talk about #galectin #drugs & potent #antiviral https://t.co/vma2hIy6CY @EnemyInAState pic.twitter.com/ARIwmsS65t

— Mike Sheikh (@MikeSheikh2) September 20, 2023

[JoeForkeyBolo]

NEWS: Bioxytran S-1 filing for Triton Funds investment to complete Phase 3 trial.

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317756483&type=PDF&symbol=BIXT&cdn=518eab6e3344025bc8b9759bf2fa0ace&companyName=Bioxytran+Inc&formType=S-1&formDescription=Registration+statement+under+Securities+Act+of+1933&dateFiled=2023-09-19

[JoeForkeyBolo]

INSIDER FINANCIAL: The Next Axcella (AXLA) Squeeze >> Bioxytran (BIXT)

https://insiderfinancial.com/the-next-axcella-axla-squeeze-bioxytran-bixt/184558/

[JoeForkeyBolo]

Made my first investment in Bioxytran this morning. Lots of potential here. Need to get Phase 3 testing funded and underway.

[INV4]

Nice day here!!
GLTA $BIXT

[cashmagnet]

Also, is there a Discord I can be invited to that features BIXT? Thanks!

[cashmagnet]

Thanks for the clarification Eco...I just opened up a position a few minutes ago and will begin adding bi-weekly until it's no longer feasible to do so...and then bide my time hoping that Bioxytran will begin to approximate Moderna's commercial success in the dim future...

[Ecomike]

BIXT has a game changer, new antiviral technology that is non toxic, that can target all of the corona viruses by blocking the spikes on them so they can attach to human cells or infect human cells. It is not just about Covid.

Also it may spin off into helping stop many autoimmune diseases caused by residual reservoirs of traces of old viral infections.

There no antivirals on the market that do anything close to what it does.

It may be like the first Antibiotic, penicillin was. A huge game changer. Nobel Prize tech.

[cashmagnet]

Right Said, Fred!! (And very well put). The Professor sees this one as a possible long hold. But after the annual variant scare passes, do you feel Bioxytran can still remain viable? In other (and fewer) words, do they have anything else in the pipeline that can generate revenue? Just curious; And thanks!

[INV4]

Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M

BIOXYTRAN, INC. | Thu, September 14, 2023

BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that its preprint article titled “Evaluation of Complex Carbohydrates Showing Broad-Spectrum Antiviral Activity Against SARS-CoV-2, Influenzas-a (H1N1), and Human Respiratory Syncytial Virus (hRSV) Strain A2 in ‘In Vitro’ Setting” (the “Article”) contains data showing a significant reduction of viral load in COVID-19, influenza (H1N1) and in human Respiratory Syncytial Virus (RSV). ProLectin-M (“PL-M”) and ProLectin-I were the galectin antagonists used on these 3 viruses to produce the results set forth in the Article.

The in vitro data demonstrates that PL-M has the potential to be a broad-spectrum antiviral useful in the treatment of Upper Respiratory Infections (“URI”). The new COVID-19 variants continue to render older COVID vaccines obsolete. While hospitalizations are on the rise, many Americans are currently offered inadequate protection and therapeutic solutions. This situation represents a large unmet medical need. Additionally, the existing antiviral treatment options have seen the first signs of resistance calling into question their long-term viability. PL-M is a next generation antiviral that is designed to prevent the virus from entering the cell. The universal nature of the binding region of the spike protein known as the Galectin Fold is expected to neutralize the virus regardless of mutation.

The full text of the preprint Article is located at the following link
https://www.preprints.org/manuscript/202309.0077/v1

About ProLectin-M
ProLectin-M is an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells. In recent clinical trials the drug achieved a 100% responders rate of negative PCR tests by day 7. In 3 days, the drug achieved an 88% responders rate of negative PCR tests. The treated population experienced no viral rebounds during the 14-day observation period. The company is preparing for a phase 3 clinical trial in order to seek regulatory approval.

About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com

Investor Relations
Michael Sheikh
509-991-0245
[e-mail]

Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

https://finance.yahoo.com/news/bioxytran-announces-broad-spectrum-antiviral-134100701.html?guccounter=1&guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=AQAAAKBUWbQ28466iPNfNwVCUFpDR8-VcflkEZKUWwTNZj27FycwTX64Hne6gEUdGDZ5PzHKaJN0uwYbiaKVc3nDt0IqQki9y6iyR-QzT4NoH3VkiS4hOJ5mSdUfEwyHBq1v7aCcY8xCEqUDKZzFq5SMbtVQRVlCLA6lR3475Vf5ddX7

$BIXT

[govprs]

They PRd this today.

[Retire43]

$BIXT: Bioxytan Inc:
www.bioxytraninc.com

https://www.preprints.org/manuscript/202309.0077/v1